PCM
XENE icon

Peregrine Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Peregrine Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.95M Buy
164,894
+21,758
+15% +$1.21M 0.32% 92
2026
Q1 		$8.32M Sell
143,136
-31,715
-18% -$1.46M 0.31% 95
2025
Q4 		$7.84M Buy
+174,851
New +$7.34M 0.24% 118

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Peregrine Capital Management's XENE Position: Q2 2026 in Review

Peregrine Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 15% in Q2 2026, buying an estimated $1.21M and bringing the position to 164,894 shares worth $9.95M. The position accounts for 0.32% of the portfolio, ranked #92.

Peregrine Capital Management first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Peregrine Capital Management held 164,894 shares of Xenon Pharmaceuticals worth $9.95M as of Q2 2026.
  • Peregrine Capital Management bought 21,758 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.21M.
  • Xenon Pharmaceuticals made up 0.32% of Peregrine Capital Management's portfolio in Q2 2026, its #92 holding.
  • Peregrine Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.